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SUPPLEMENTAL MATERIAL 
Georgakis et al. Circulating monocyte chemoattractant protein-1 and risk of stroke: a meta-analysis of 
population-based studies involving 17,180 individuals. 
 
Appendix I. Search strategy. 
Online Table I. Summary of the study design, population characteristics, methods used for quantifying 
circulating MCP-1 levels, stroke outcome definitions, and assessments in the cohorts included in the 
meta-analysis. 
Online Table II. Quality characteristics of the included studies according to the Newcastle-Ottawa Scale. 
Online Table III. Associations between baseline circulating MCP-1 levels and risk of any stroke. Shown 
are the results from random-effects meta-analyses across the different models in the pooled sample 
consisting of six population-based studies. 
Online Table IV. Associations between baseline circulating MCP-1 levels and risk of ischemic stroke. 
Shown are the results from random-effects meta-analyses across the different models in the pooled 
sample consisting of six population-based studies. 
Online Table V. Associations between baseline circulating MCP-1 levels and risk of hemorrhagic stroke. 
Shown are the results from random-effects meta-analyses across the different models in the pooled 
sample consisting of six population-based studies. 
Online Table VI. Meta-regression analyses for the effect of different study characteristics on the 
association between ln-transformed MCP-1 circulating levels at baseline (1 SD increment) with any 
stroke and etiological stroke subtypes (ischemic and hemorrhagic stroke).   
Online Table VII. Associations between baseline circulating hsCRP, IL-6, and MCP-1 levels and risk of 
any stroke, ischemic stroke, and hemorrhagic stroke. Shown are the results from random-effects meta-
analyses of the pooled sample consisting of four population-based studies, where both hsCRP and IL-6 
levels were available. 
Online Figure I. Flowchart of the study selection for the systematic review. 
Online Figure II. Study-specific and pooled hazard ratios for incident any stroke per standard deviation 
increase in ln-transformed circulating MCP-1 levels and across MCP-1 level quartiles. Shown are the 
results from random-effects meta-analyses.  
Online Figure III. Study-specific and pooled hazard ratios for incident ischemic stroke per standard 
deviation increase in ln-transformed circulating MCP-1 levels and across MCP-1 level quartiles. Shown 
are the results from random-effects meta-analyses (Model 2).  
Online Figure IV. Study-specific and pooled hazard ratios for incident hemorrhagic stroke per standard 
deviation increase in ln-transformed circulating MCP-1 levels and across MCP-1 level quartiles. Shown 
are the results from random-effects meta-analyses (Model 2).  
Online Figure V. Pooled hazard ratios for incident fatal and non-fatal stroke per circulating MCP-1 
levels, as derived from random-effects meta-analyses (Model 2). 
Online Figure VI. Pooled hazard ratios for incident any stroke per standard deviation increase in ln-
transformed circulating MCP-1 levels and across MCP-1 level quartiles in sensitivity analyses omitting 
one study per time. Shown are the results from random-effects meta-analyses.  
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Online Figure VII. Pooled hazard ratios for incident ischemic stroke per standard deviation increase in 
ln-transformed circulating MCP-1 levels and across MCP-1 level quartiles in sensitivity analyses omitting 
one study per time. Shown are the results from random-effects meta-analyses.  
Online Figure VIII. Pooled hazard ratios for incident hemorrhagic stroke per standard deviation increase 
in ln-transformed circulating MCP-1 levels and across MCP-1 level quartiles in sensitivity analyses 
omitting one study per time. Shown are the results from random-effects meta-analyses.  
Online Figure IX. Pooled hazard ratios for incident ischemic stroke per standard deviation increase in ln-
transformed circulating MCP-1 levels, as derived from random-effects meta-analyses stratified by pre-
defined study variables. 
Online References.  
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Appendix I. Search strategy. 
(CCL2 OR MCP1 OR CCL-2 OR MCP-1 OR “monocyte chemoattractant protein 1” OR “small inducible 
cytokine A2” OR “chemokine (C-C motif) ligand 2” OR “C-C motif ligand 2”) AND (stroke OR 
cerebrovascular OR (coronary AND artery AND disease) OR (ischemic AND heart AND disease) OR 
(myocardial AND infarction)) 
1303 results in PubMed by March 15th 2019 
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Online Table I. Summary of the study design, population characteristics, methods used for quantifying circulating MCP-1 levels, stroke outcome definitions, and 
assessments in the cohorts included in the meta-analysis. 
Cohort Study design Population characteristics MCP-1 quantification Definition-assessment of stroke 
Atherosclerosis Risk in 
Communities (ARIC) 
A sub-sample of the population-based 
prospective ARIC cohort study with 
available measurements on MCP-11  
 
Inhabitants of 4 US communities 
(Forsyth County, North Carolina; 
Jackson, Mississippi; the 
northwestern suburbs of 
Minneapolis, Minnesota; and 
Washington County, Maryland) 
aged 45-64 years 
Duplicate measurements using direct 
sandwich ELISA (Amersham 
Pharmacia Biotech Inc., Piscataway, 
NJ, USA) in fasting plasma samples 
(stored at -70 °C) 
Non-fatal and fatal stroke were defined through linkage with the 
hospital records for possible stroke‐related hospitalizations 
(International Classification of Diseases, Ninth Revision [ICD‐9] 
codes 430–438 until 1997 and codes 430–436 afterwards) and the 
National Death Index for stroke deaths; physician reviewers 
adjudicated all possible strokes and classified them as definite or 
probable ischemic and hemorrhagic events2 
Dallas Heart Study (DHS) 
A sub-sample of a population-based 
prospective cohort study designed to study 
cardiovascular disease with available 
measurements on MCP-13 
Multi-ethnic stratified random 
sample of Dallas County, US, 
residents aged 30-65 years 
Duplicate measurements using 
immunoassay (BIOSITE Inc., San 
Diego, CA) on a high-throughput 
robotic platform (TECAN Genesis 
RSP 200/8) in fasting plasma samples 
(stored at -80 °C) 
Non-fatal stroke was defined by either assessment of medical 
records during annual follow-up assessments or by tracking 
hospital admissions through the Dallas–Fort Worth Hospital 
Council Data Initiative database (coverage 90% of the study 
region) using the ICD 9 codes 430-438; fatal stroke was defined by 
death certification using the National Death Index according to the 
ICD 10 codes I60-I694  
European Prospective 
Investigation of Cancer (EPIC) - 
Norfolk study 
Secondary analysis of a nested case-
control study within the prospective 
population-based EPIC-Norfolk cohort of 
cases with coronary artery disease and 
healthy controls5 
Inhabitants of Norfolk, UK, aged 
45-79 years who were free of stroke 
and myocardial infarction at 
baseline 
Multiplex assay using the Bioplex 
Suspension Array (Bio-Rad, 
Veenendaal, the Netherlands) in non-
fasting serum samples (stored at -80 
°C) 
Non-fatal stroke was defined by hospital admission record linkage 
with the NHS hospital information system and ENCORE (East 
Norfolk COmmission Record; fatal stroke was defined by death 
certification derived from the Office of National Statistics, and was 
defined according to the ICD 9 codes 430-438, or the ICD 10 
codes I60-I696  
Framingham Heart Study (FHS) - 
Offspring Cohort 
Participants of the community-based 
prospective cohort FHS study who 
attended the examination cycle 7 (1998-
2001)7 
Offspring of the participants of the 
Original Cohort of the FHS and 
their spouses aged 33-90 years 
Duplicate measurements using a 
commercially available ELISA (R&D 
Systems) in fasting serum samples 
(stored at -70 °C)8 
Stroke was defined as rapidly developing signs of focal neurologic 
disturbance of presumed vascular etiology lasting more than 24 
hours as part of an ongoing clinic and hospital surveillance 
including medical record review; laboratory testing; imaging; 
autopsy findings; and collaboration with general practitioners, 
emergency departments, and imaging facilities in the area9 
Monitoring of Trends and 
Determinants in Cardiovascular 
Disease sub-cohort of the 
Cooperative Health Research in 
the Region of Augsburg 
(MONICA/ KORA) 
Secondary analysis of a case-cohort study 
within the prospective population-based 
MONICA/KORA cohort of incident cases 
with coronary artery disease and a 
representative sub-cohort of 
MONICA/KORA sample10 
Inhabitants of Augsburg and 
surrounding counties, Germany, 
aged 25-74 years  
Luminex multiplex technology using 
a Luminex 100 analyzer (Luminex 
Corporation, Austin, TX, recombinant 
proteins and antibodies purchased 
from R&D systems) in non-fasting 
serum samples (stored at -80 °C) 
Non-fatal stroke was defined by self-report validated by cross-
linkage with hospital records and information gathered from the 
treating physicians of the participants; fatal stroke was defined by 
death certification derived from local health authorities and was 
defined according to the ICD 9 codes 430-434 (German modified 
version)11  
Malmö Diet and Cancer Study 
(MDCS) - Cardiovascular (CV) 
sub-cohort  
A random 50% sub-sample of the 
population-based prospective cohort 
MDCS study were included in the MDCS-
CV sub-cohort designed to examine 
cardiovascular disease12 
Inhabitants of Malmö, Sweden, 
aged 45-64 years  
Proximity Extension Assay technique 
using the Proseek Multiplex 
CVD96x96 reagents kit (Olink 
Bioscience) in fasting plasma samples 
(stored at -80 °C) 
Non-fatal and fatal stroke were defined by record linkage with the 
National Inpatient Register, the Swedish Causes of Death Register, 
and the Stroke Register of Malmö (STROMA) and was defined 
according to the ICD 9 codes 430-43813 
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Online Table II. Quality characteristics of the included studies according to the Newcastle-Ottawa Scale. 
Cohort ARIC DHS 
EPIC-
Norfolk 
FHS 
Offspring 
MONICA/KORA MDCS-CV 
Selection items       
Representativeness of exposed cohort (general population study) * * * * * * 
Selection of the non-exposed cohort (patients selected independently of MCP-1 levels) * * * * * * 
Ascertainment of exposure (serum/plasma MCP-1 levels assessed with validated assay) * * * * * * 
Outcome not present a start of study (exclusion of prevalent stroke cases from analysis) * * * * * * 
Comparability items       
Adjustments on age, sex, race * * * * * * 
Adjustments on vascular risk factors * * * * * * 
Outcome items       
Assessment of outcome (assessment through medical records, hospital admission records, 
and death certificates) 
* * * * * * 
Length of follow-up (>5 years) * * * * * * 
Adequacy of follow-up cohorts (<10% lost to follow-up rates) * * * * * * 
Total score 9/9 9/9 9/9 9/9 9/9 9/9 
  
6 
 
Online Table III. Associations between baseline circulating MCP-1 levels and risk of any stroke. Shown are the results from random-effects meta-analyses across the 
different models in the pooled sample consisting of six population-based studies. 
  Model 1    Model 2    
Alternative 
Model 2 
   Model 3  
Variables in the models HR 95%CI p  HR 95%CI p  HR 95%CI p  HR 95%CI p 
Age (1-yr increment) 1.09 (1.07-1.12) 7E-13  1.08 (1.05-1.11) 7E-8  1.07 (1.04-1.11) 2E-6  1.08 (1.05-1.11) 2E-7 
Sex (males vs. females) 1.26 (0.98-1.62) 0.067  1.21 (1.00-1.48) 0.056  1.13 (0.93-1.36) 0.214  1.22 (1.00-1.48) 0.051 
Hypertension (yes vs. no)     1.80 (1.58-2.04) 2E-19      1.78 (1.57-2.03) 1E-20 
SBP (10 mmHg-increment)         1.16 (1.12-1.19) 3E-18     
Intake of antihypertensive medication         1.47 (1.29-1.67) 5E-9     
Diabetes (yes vs. no)     1.739 (1.27-2.38) 0.001      1.79 (1.26-2.53) 0.001 
Fasting glucose levels (10 mg/dl increment)         1.03 (1.00-1.07) 0.04     
Intake of glucose-lowering medication         1.33 (0.93-1.91) 0.117     
Smoking (current vs. non-current)     1.594 (0.99-2.56) 0.054  1.52 (0.94-2.46) 0.086  1.51 (0.98-2.34) 0.062 
Hypercholesterolemia (yes vs. no)     1.021 (0.88-1.19) 0.784      1.02 (0.89-1.16) 0.804 
LDL-C levels (10 mg/dl increment)         1.01 (0.99-1.02) 0.406     
HDL-C levels (5 mg/dl increment)         0.98 (0.95-1.01) 0.269     
Intake of lipid-lowering medication         1.05 (0.82-1.35) 0.694     
Chronic kidney disease (yes vs. no)     1.00 (0.89-1.12) 0.999      0.97 (0.89-1.06) 0.546 
eGFR (10 ml/min/1.73 m2 increment)         1.00 (0.99-1.00) 0.48     
BMI (5 kg/m2 increment)     1.01 (0.91-1.11) 0.896  0.96 (0.87-1.05) 0.336  0.97 (0.95-1.00) 0.044 
Heart failure (yes vs. no)      1.18 (0.80-1.73) 0.402  1.35 (0.91-1.99) 0.134  1.18 (0.80-1.76) 0.405 
Coronary artery disease (yes vs. no)     1.80 (1.38-2.34) 2E-5  1.74 (1.32-2.29) 8E-5  1.76 (1.35-2.31) 4E-5 
Atrial fibrillation (yes vs. no)     1.50 (0.94-2.39) 0.091  1.48 (0.92-2.36) 0.106  1.51 (0.94-2.41) 0.086 
ln-hsCRP (1-SD increment)             1.12 (1.05-1.19) 0.0003 
ln-MCP1 (1-SD increment) 1.10 (1.01-1.19) 0.018  1.07 (1.01-1.14) 0.028  1.07 (1.00-1.15) 0.035  1.07 (1.00-1.14) 0.053 
1st quartile  reference    reference    reference    Reference  
2nd quartile 1.17 (1.00-1.37) 0.058  1.16 (0.99-1.36) 0.075  1.16 (0.98-1.38) 0.079  1.18 (1.00-1.38) 0.048 
3rd quartile 1.35 (1.16-1.57) 0.0001  1.31 (1.12-1.53) 0.001  1.35 (1.14-1.58) 0.0003  1.32 (1.13-1.55) 0.0004 
4th quartile 1.43 (1.10-1.86) 0.004  1.33 (1.05-1.68) 0.008  1.37 (1.09-1.72) 0.005  1.34 (1.08-1.65) 0.007 
All models are additionally adjusted for race, but following study-specific classifications that precluded meta-analysis for this variable. 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; BMI, body mass 
index; hsCRP, high-sensitivity C-reactive protein; MCP-1, monocyte-chemoattractant protein 1; HR, hazard ratio; SD, standard deviation. 
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Online Table IV. Associations between baseline circulating MCP-1 levels and risk of ischemic stroke. Shown are the results from random-effects meta-analyses across 
the different models in the pooled sample consisting of six population-based studies. 
  Model 1    Model 2    
Alternative 
Model 2 
   Model 3  
Variables in the models HR 95%CI p  HR 95%CI p  HR 95%CI p  HR 95%CI p 
Age (1-yr increment) 1.10 (1.07-1.12) 4E-13  1.08 (1.05-1.11) 7E-7  1.08 (1.04-1.11) 7E-6  1.08 (1.05-1.11) 4E-7 
Sex (males vs. females) 1.28 (1.00-1.64) 0.050  1.22 (1.02-1.45) 0.029  1.12 (0.94-1.34) 0.193  1.23 (1.03-1.46) 0.022 
Hypertension (yes vs. no)     1.80 (1.57-2.06) 3E-17      1.78 (1.55-2.05) 4E-16 
SBP (10 mmHg-increment)         1.15 (1.10-1.20) 3E-11     
Intake of antihypertensive medication         1.52 (1.32-1.75) 3E-9     
Diabetes (yes vs. no)     1.88 (1.33-2.64) 0.0003      1.90 (1.32-2.72) 0.001 
Fasting glucose levels (10 mg/dl increment)         1.04 (1.01-1.07) 0.013     
Intake of glucose-lowering medication         1.33 (0.90-1.96) 0.154     
Smoking (current vs. non-current)     1.55 (0.95-2.54) 0.082  1.47 (0.89-2.44) 0.137  1.48 (0.93-2.34) 0.097 
Hypercholesterolemia (yes vs. no)     1.09 (0.92-1.28) 0.314      1.09 (0.94-1.26) 0.260 
LDL-C levels (10 mg/dl increment)         1.01 (1.00-1.03) 0.112     
HDL-C levels (5 mg/dl increment)         0.98 (0.96-1.01) 0.243     
Intake of lipid-lowering medication         1.12 (0.86-1.47) 0.404     
Chronic kidney disease (yes vs. no)     0.97 (0.85-1.11) 0.664      0.94 (0.85-1.03) 0.198 
eGFR (10 ml/min/1.73 m2 increment)         1.00 (0.99-1.00) 0.268     
BMI (5 kg/m2 increment)     1.01 (0.90-1.13) 0.877  0.95 (0.84-1.07) 0.412  0.99 (0.92-1.06) 0.721 
Heart failure (yes vs. no)      1.16 (0.76-1.77) 0.501  1.29 (0.84-2.00) 0.246  1.16 (0.75-1.81) 0.508 
Coronary artery disease (yes vs. no)     1.74 (1.22-2.48) 0.002  1.64 (1.13-2.38) 0.009  1.55 (0.97-2.48) 0.068 
Atrial fibrillation (yes vs. no)     1.54 (0.94-2.54) 0.088  1.53 (0.93-2.54) 0.097  1.56 (0.95-2.56) 0.083 
ln-hsCRP (1-SD increment)             1.14 (1.07-1.22) 0.0002 
ln-MCP1 (1-SD increment) 1.12 (1.03-1.23) 0.007  1.11 (1.02-1.21) 0.009  1.11 (1.02-1.21) 0.011  1.10 (1.01-1.21) 0.018 
1st quartile  reference    reference    reference    reference  
2nd quartile 1.19 (1.01-1.41) 0.039  1.19 (1.00-1.42) 0.047  1.17 (0.97-1.41) 0.089  1.22 (1.03-1.45) 0.022 
3rd quartile 1.38 (1.17-1.63) 0.0001  1.35 (1.14-1.59) 0.0004  1.38 (1.16-1.65) 0.0003  1.36 (1.15-1.60) 0.0003 
4th quartile 1.43 (1.11-1.85) 0.003  1.38 (1.07-1.77) 0.008  1.39 (1.10-1.76) 0.006  1.38 (1.10-1.74) 0.004 
All models are additionally adjusted for race, but following study-specific classifications that precluded meta-analysis for this variable. 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; BMI, body mass 
index; hsCRP, high-sensitivity C-reactive protein; MCP-1, monocyte-chemoattractant protein 1; HR, hazard ratio; SD, standard deviation.
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Online Table V. Associations between baseline circulating MCP-1 levels and risk of hemorrhagic stroke. Shown are the results from random-effects meta-analyses 
across the different models in the pooled sample consisting of six population-based studies. 
  Model 1    Model 2    
Alternative 
Model 2 
   Model 3  
Variables in the models HR 95%CI p  HR 95%CI p  HR 95%CI p  HR 95%CI p 
Age (1-yr increment) 1.08 (1.06-1.10) 0  1.08 (1.05-1.10) 7E-10  1.06 (1.03-1.09) 7E-5  1.07 (1.03-1.11) 0.0001 
Sex (males vs. females) 1.05 (0.62-1.78) 0.847  1.04 (0.63-1.71) 0.879  0.82 (0.49-1.37) 0.446  0.89 (0.64-1.22) 0.453 
Hypertension (yes vs. no)     1.94 (1.39-2.71) 0.0001      1.95 (1.39-2.73) 0.0001 
SBP (10 mmHg-increment)         1.23 (1.14-1.34) 3E-7     
Intake of antihypertensive medication         1.32 (0.82-2.13) 0.250     
Diabetes (yes vs. no)     1.05 (0.67-1.65) 0.832      1.05 (0.66-1.65) 0.842 
Fasting glucose levels (10 mg/dl increment)         0.95 (0.88-1.03) 0.224     
Intake of glucose-lowering medication         2.81 (0.94-8.38) 0.065     
Smoking (current vs. non-current)     1.57 (0.90-2.73) 0.110  1.49 (0.82-2.72) 0.193  1.36 (0.96-1.92) 0.087 
Hypercholesterolemia (yes vs. no)     0.83 (0.59-1.17) 0.286      0.80 (0.56-1.13) 0.199 
LDL-C levels (10 mg/dl increment)         0.98 (0.94-1.03) 0.465     
HDL-C levels (5 mg/dl increment)         1.05 (0.93-1.18) 0.417     
Intake of lipid-lowering medication         1.05 (0.48-2.32) 0.905     
Chronic kidney disease (yes vs. no)     1.17 (0.76-1.81) 0.474      1.17 (0.75-1.82) 0.487 
eGFR (10 ml/min/1.73 m2 increment)         1.00 (0.92-1.10) 0.937     
BMI (5 kg/m2 increment)     0.93 (0.75-1.15) 0.493  0.94 (0.71-1.23) 0.645  0.94 (0.83-1.07) 0.330 
Heart failure (yes vs. no)      6.93 (1.65-29.2) 0.008  12.0 (3.46-41.7) 9E-5  6.52 (1.24-34.2) 0.027 
Coronary artery disease (yes vs. no)     1.30 (0.49-3.48) 0.601  1.37 (0.50-3.76) 0.547  1.42 (0.53-3.86) 0.488 
Atrial fibrillation (yes vs. no)     3.97 (0.94-16.7) 0.061  3.83 (0.89-16.4) 0.071  3.90 (0.93-16.4) 0.064 
ln-hsCRP (1-SD increment)             1.13 (0.96-1.34) 0.140 
ln-MCP1 (1-SD increment) 1.05 (0.84-1.30) 0.669  1.02 (0.82-1.29) 0.833  1.04 (0.79-1.37) 0.776  1.02 (0.80-1.31) 0.844 
1st quartile  reference    reference    reference    reference  
2nd quartile 0.96 (0.62-1.50) 0.873  0.95 (0.61-1.47) 0.807  0.97 (0.60-1.57) 0.907  0.96 (0.62-1.49) 0.860 
3rd quartile 1.27 (0.84-1.92) 0.251  1.25 (0.82-1.91) 0.293  1.31 (0.80-2.15) 0.276  1.27 (0.84-1.93) 0.252 
4th quartile 1.09 (0.71-1.66) 0.692  1.02 (0.66-1.56) 0.945  1.07 (0.67-1.71) 0.768  1.02 (0.67-1.57) 0.921 
All models are additionally adjusted for race, but following study-specific classifications that precluded meta-analysis for this variable. The Dallas Heart Study (DHS) is not included in any of the analyses for hemorrhagic stroke due 
to the low number of events. The Atherosclerosis Risk in Community (ARIC) study is not included in the quartile analyses. 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; BMI, body mass 
index; hsCRP, high-sensitivity C-reactive protein; MCP-1, monocyte-chemoattractant protein 1; HR, hazard ratio; SD, standard deviation.
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Online Table VI. Meta-regression analyses for the effect of different study characteristics on the association between ln-
transformed MCP-1 circulating levels at baseline (1 SD increment) with any stroke and etiological stroke subtypes 
(ischemic and hemorrhagic stroke).   
 Any stroke Ischemic stroke Hemorrhagic stroke 
Variable 
Exponentiated 
regression coefficient 
(95% CI) 
p 
Exponentiated 
regression coefficient 
(95% CI) 
p 
Exponentiated 
regression coefficient 
(95% CI) 
p 
Age (1y-increment) 0.993 (0.979-1.007) 0.24 0.989 (0.974-1.005) 0.12 1.002 (0.914-1.099) 0.95 
Males (5%-increment) 1.003 (0.941-1.068) 0.91 0.994 (0.919-1.075) 0.85 1.063 (0.950-1.190) 0.18 
SBP (10 mmHg-increment) 0.932 (0.814-1.066) 0.22 0.897 (0.774-1.040) 0.11 1.065 (0.540-2.097) 0.79 
Diabetes (5%-increment) 0.987 (0.903-1.079) 0.71 0:983 (0.877-1.102) 0.69 1.063 (0.857-1.320) 0.43 
LDL-C (10 mg/dl-increment) 0.984 (0.933-1.037) 0.43 0.968 (0.919-1.020) 0.16 1.054 (0.833-1.335) 0.53 
BMI (5kg/m2-increment) 1.160 (0.776-1.734) 0.36 1.298 (0.856-1.970) 0.16 0.978 (0.098-9.707) 0.98 
Current smokers (5%-increment) 0.997 (0.937-1.061) 0.91 0.994 (0.917-1.077) 0.84 1.076 (0.950-1.219) 0.16 
eGFR (10ml/min/1.73m2-increment) 1.064 (0.971-1.166) 0.13 1.090 (0.987-1.203) 0.07 1.016 (0.592-1.743) 0.93 
Coronary artery disease (5%-increment) 1.033 (0.870-1.227) 0.63 1.058 (0.877-1.277) 0.45 0.830 (0.510-1.351) 0.31 
hsCRP (1 unit-increment in ln(hsCRP)) 1.028 (0.696-1.517) 0.84 1.125 (0.643-1.971) 0.55 0.992 (0.102-9.615) 0.99 
Sample (serum vs. plasma) 0.985 (0.800-1.247) 0.88 0.943 (0.704-1.262) 0.61 1.043 (0.443-2.457) 0.89 
 
Abbreviations: BMI, body mass index; hsCRP, high-sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; LDL, low-density liporprotein; MCP-
1, monocyte chemoattractant protein- 1; SBP, systolic blood pressure.    
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Online Table VII. Associations between baseline circulating hsCRP, IL-6, and MCP-1 levels and risk of any stroke, ischemic stroke, and hemorrhagic stroke. Shown are 
the results from random-effects meta-analyses of the pooled sample consisting of four population-based studies, where both hsCRP and IL-6 levels were available. 
      Any stroke  Ischemic stroke  Hemorrhagic stroke * 
Variables in the models Population Follow-up (y) Events HR 95%CI p  Events HR 95%CI p  Events HR 95%CI p 
Model adjusted for age, sex, race, vascular risk factors† 
ln-MCP1 (1-SD increment) 12686 15.6 777 1.08 (1.00-1.16) 0.056  634 1.12 (1.02-1.24) 0.020  108 0.90 (0.74-1.10) 0.298 
1st quartile 3184 15.7 145  reference   114  reference   26  reference  
2nd quartile 3162 15.7 177 1.09 (0.87-1.37) 0.468  144 1.12 (0.87-1.43) 0.390  24 0.95 (0.51-1.79) 0.876 
3rd quartile 3177 15.6 212 1.21 (0.98-1.50) 0.080  175 1.27 (1.01-1.62) 0.044  31 1.15 (0.58-2.28) 0.692 
4th quartile 3163 15.3 243 1.33 (1.05-1.69) 0.014  201 1.43 (1.04-1.97) 0.022  27 0.91 (0.52-1.60) 0.745 
Model adjusted for age, sex, race, vascular risk factors†, hsCRP levels 
ln-hsCRP (1-SD increment) 12519 15.6 773 1.11 (1.03-1.20) 0.009  616 1.14 (1.05-1.24) 0.003  107 1.03 (0.83-1.26) 0.803 
ln-MCP1 (1-SD increment) 12519 15.6 773 1.06 (0.98-1.14) 0.098  616 1.12 (1.00-1.26) 0.048  107 0.91 (0.74-1.10) 0.321 
1st quartile 3155 15.7 142  reference   110  reference   25  reference  
2nd quartile 3128 15.7 178 1.09 (0.87-1.36) 0.449  143 1.12 (0.87-1.44) 0.374  24 0.95 (0.51-1.77) 0.870 
3rd quartile 3138 15.6 213 1.22 (0.98-1.51) 0.073  174 1.28 (1.01-1.63) 0.041  31 1.16 (0.59-2.29) 0.661 
4th quartile 3098 15.3 240 1.32 (1.02-1.72) 0.039  189 1.42 (1.03-1.99) 0.037  27 0.92 (0.52-1.62) 0.777 
Model adjusted for age, sex, race, vascular risk factors†, IL-6 levels 
ln-IL-6 (1-SD increment) 12516 15.6 758 1.12 (1.04-1.21) 0.003  614 1.17 (1.02-1.35) 0.025  107 1.12 (0.92-1.36) 0.251 
ln-MCP1 (1-SD increment) 12516 15.6 769 1.05 (0.98-1.4) 0.146  614 1.12 (0.99-1.28) 0.064  107 0.88 (0.72-1.08) 0.210 
1st quartile 3168 15.7 142  reference   109  reference   25  reference  
2nd quartile 3148 15.7 177 1.09 (0.87-1.36) 0.465  142 1.10 (0.86-1.42) 0.445  24 0.96 (0.49-1.88) 0.901 
3rd quartile 3160 15.6 212 1.20 (0.96-1.49) 0.098  174 1.24 (0.97-1.58) 0.079  31 1.13 (0.56-2.27) 0.736 
4th quartile 3141 15.3 238 1.31 (0.97-1.76) 0.086  189 1.39 (0.99-1.96) 0.052  27 0.86 (0.48-1.53) 0.611 
Model adjusted for age, sex, race, vascular risk factors†, hsCRP, and IL-6 levels 
ln-hsCRP (1-SD increment) 12516 15.6 758 1.08 (1.00-1.19) 0.058  610 1.12 (1.02-1.23) 0.018  107 0.88 (0.79-1.23) 0.877 
ln-IL-6 (1-SD increment) 12516 15.6 758 1.09 (1.00-1.19) 0.041  610 1.13 (0.96-1.35) 0.137  107 1.13 (0.92-1.40) 0.248 
ln-MCP1 (1-SD increment) 12516 15.6 758 1.05 (0.98-1.13) 0.178  610 1.12 (0.98-1.29) 0.078  107 0.88 (0.72-1.08) 0.234 
1st quartile 3168 15.7 141  reference   107  reference   25  reference  
2nd quartile 3148 15.7 176 1.10 (0.88-1.37) 0.422  141 1.12 (0.87-1.44) 0.398  24 0.96 (0.49-1.88) 0.914 
3rd quartile 3160 15.6 211 1.21 (0.98-1.51) 0.078  173 1.26 (0.99-1.61) 0.059  31 1.14 (0.56-2.30) 0.718 
4th quartile 3141 15.3 230 1.30 (0.97-1.76) 0.096  189 1.39 (0.98-1.99) 0.063  27 0.88 (0.49-1.56) 0.660 
The Atherosclerosis Risk in Community (ARIC) and the European Prospective Investigation of Cancer-Norfolk (EPIC-Norfolk) studies are not included in these analyses because of non-availability of data on IL-6 levels. 
* The Dallas Heart Study (DHS) is not included in any of the analyses for hemorrhagic stroke due to the low number of events.  
† Vascular risk factors included the models are: body mass index (1 kg/m2 increment), smoking (current vs. non-current), estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery disease, diabetes 
mellitus, hypertension, hypercholesterolemia, atrial fibrillation, and heart failure at baseline. 
Abbreviations: MCP-1, monocyte-chemoattractant protein 1; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; HR, hazard ratio; SD, standard deviation.  
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Online Figure I. Flowchart of the study selection for the systematic review. 
 
   
Screened by title/abstract
(n = 1,321)
Excluded (n = 1,247)
Assessed for eligibility by full-text
(n = 74)
Excluded (n = 67):
• Not population-based studies (n = 25)
• Associations with outcomes after CAD/MI (n = 16)
• Associations with outcomes after stroke (n = 13)
• Associations with recurrent stroke/MI events (n = 9)
• Only assessing mortality as an outcome (n = 2)
• Reviews (n = 2)
• Overlap (n = 1)
Met eligibility criteria - contact with authors
(n = 7)
Articles from Pubmed
(n = 1,303)
Articles from snowball
(n = 18)
Excluded (n = 1):
• Did not provide data (n = 1)
Studies included in meta-analysis (n = 6)
• ARIC: 1234 individuals, 23 yrs of follow-up 
153 incident stroke events
• DHS: 2931 individuals, 11 yrs of follow-up, 64 
incident stroke events
• EPIC-Norfolk: 3182 individuals, 17 yrs of 
follow-up, 503 incident stroke events
• FHS Offspring: 3069 individuals, 14 yrs of 
follow-up, 172 incident stroke events
• MONICA/KORA: 2055 individuals, 16 yrs of 
follow-up, 116 incident stroke events
• MDCS-CV: 4709 individuals, 20 yrs of follow-
up, 427 incident stroke events
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Online Figure II. Study-specific and pooled hazard ratios for incident any stroke per standard 
deviation increase in ln-transformed circulating MCP-1 levels and across MCP-1 level 
quartiles. Shown are the results from random-effects meta-analyses (Model 2).  
 
 
 
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment),  
smoking (current vs. non-current), estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery 
disease, diabetes mellitus, hypertension, hypercholesterolemia, atrial fibrillation, and heart failure at baseline. 
Analyses for 1 SD increment correspond to ln-transformed MCP-1 levels.  
The gray squares around the point estimates correspond to the weight of the included studies in the meta-analysis.  
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; DHS, Dallas Heart Study; EPIC, European Prospective 
Investigation of Cancer; FHS Framingham Heart Study; KORA, Kooperative Gesundheitsforschung in der Region Augsburg; 
MDCS, Malmö Diet and Cancer Study.  
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Online Figure III. Study-specific and pooled hazard ratios for incident ischemic stroke per 
standard deviation increase in ln-transformed circulating MCP-1 levels and across MCP-1 level 
quartiles. Shown are the results from random-effects meta-analyses (Model 2).  
 
 
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment),  
smoking (current vs. non-current), estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery 
disease, diabetes mellitus, hypertension, hypercholesterolemia, atrial fibrillation, and heart failure at baseline. 
Analyses for 1 SD increment correspond to ln-transformed MCP-1 levels.  
The gray squares around the point estimates correspond to the weight of the included studies in the meta-analysis.  
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; DHS, Dallas Heart Study; EPIC, European Prospective 
Investigation of Cancer; FHS Framingham Heart Study; KORA, Kooperative Gesundheitsforschung in der Region Augsburg; 
MDCS, Malmö Diet and Cancer Study. 
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Online Figure IV. Study-specific and pooled hazard ratios for incident hemorrhagic stroke per 
standard deviation increase in ln-transformed circulating MCP-1 levels and across MCP-1 level 
quartiles. Shown are the results from random-effects meta-analyses (Model 2).  
 
 
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment), 
smoking (current vs. non-current), estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery 
disease, diabetes mellitus, hypertension, hypercholesterolemia, atrial fibrillation, and heart failure at baseline. 
Analyses for 1 SD increment correspond to ln-transformed MCP-1 levels.  
The Dallas Heart Study (DHS) is not included in any of the analyses for hemorrhagic stroke due to the low number of events. 
The Atherosclerosis Risk in Community (ARIC) study is not included in the quartile analyses due to the low number of events. 
The gray squares around the point estimates correspond to the weight of the included studies in the meta-analysis.  
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; EPIC, European Prospective Investigation of Cancer; FHS 
Framingham Heart Study; KORA, Kooperative Gesundheitsforschung in der Region Augsburg; MDCS, Malmö Diet and Cancer 
Study.  
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Online Figure V. Pooled hazard ratios for incident fatal and non-fatal stroke per circulating MCP-1 levels, 
as derived from random-effects meta-analyses. 
 
Analyses correspond to 1 SD increment in ln-transformed MCP-1 levels and represent pooled results of meta-analyses of all six studies. 
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment),  smoking 
(current vs. non-current), estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery disease, diabetes 
mellitus, hypertension, hypercholesterolemia, atrial fibrillation, and heart failure at baseline (Model 2). 
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Online Figure VI. Pooled hazard ratios for incident any stroke per standard deviation increase in ln-
transformed circulating MCP-1 levels and across MCP-1 level quartiles in sensitivity analyses omitting one 
study per time. Shown are the results from random-effects meta-analyses.  
 
 
(A) 1 SD increment         (B) Q2 vs. Q1 
  
(C) Q3 vs. Q1          (D) Q4 vs. Q1 
   
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment),  smoking (current vs. non-current), 
estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery disease, diabetes mellitus, hypertension, hypercholesterolemia, atrial 
fibrillation, and heart failure at baseline. 
Analyses for 1 SD increment correspond to ln-transformed MCP-1 levels.  
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Online Figure VII. Pooled hazard ratios for incident ischemic stroke per standard deviation increase in ln-
transformed circulating MCP-1 levels and across MCP-1 level quartiles in sensitivity analyses omitting 
one study per time. Shown are the results from random-effects meta-analyses.  
 
 
(B) 1 SD increment         (B) Q2 vs. Q1 
  
(D) Q3 vs. Q1          (D) Q4 vs. Q1 
   
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment),  smoking (current vs. non-current), 
estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery disease, diabetes mellitus, hypertension, hypercholesterolemia, atrial 
fibrillation, and heart failure at baseline. 
Analyses for 1 SD increment correspond to ln-transformed MCP-1 levels.  
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Online Figure VIII. Pooled hazard ratios for incident hemorrhagic stroke per standard deviation increase 
in ln-transformed circulating MCP-1 levels and across MCP-1 level quartiles in sensitivity analyses 
omitting one study per time. Shown are the results from random-effects meta-analyses.  
 
 
(C) 1 SD increment         (B) Q2 vs. Q1 
  
(E) Q3 vs. Q1          (D) Q4 vs. Q1 
   
The results are derived from Cox proportional hazard models adjusted for age, sex, race, body mass index (1 kg/m2 increment),  smoking (current vs. non-current), 
estimated glomerular filtration rate (1 mL/min/1.73 m² increment), history of coronary artery disease, diabetes mellitus, hypertension, hypercholesterolemia, atrial 
fibrillation, and heart failure at baseline. 
Analyses for 1 SD increment correspond to ln-transformed MCP-1 levels.  
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Online Figure IX. Pooled hazard ratios for incident ischemic stroke per standard deviation increase in 
ln-transformed circulating MCP-1 levels, as derived from random-effects meta-analyses stratified by pre-
defined study variables. 
 
 
The p-values (p) correspond to the results of the random-effects meta-analyses and test statistical significance for the hazard ratios, whereas the 
p-values for heterogeneity (p-het) correspond to the Cochran Q test and test for statistical significance for the presence of heterogeneity in the 
respective meta-analysis. The results of heterogeneity between the pooled effects across the different variable categories are presented under the 
results for each variable. 
The gray squares around the point estimates correspond to the weight of the included studies in the meta-analysis.  
* ARIC has not been included in these analyses. 
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